Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?

Autor:	Favresse J; Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium.; Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium., Tré-Hardy M; Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium.; Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.; Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium., Gillot C; Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium., Cupaiolo R; Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium., Wilmet A; Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium., Beukinga I; Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium., Blairon L; Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium., Bayart JL; Department of Laboratory Medicine, Clinique St-Pierre, Ottignies, Belgium., Closset M; Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Namur, Belgium., Wauthier L; Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium., Cabo J; Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium., David C; Qualiblood s.a., Research and Development Department, Namur, Belgium., Elsen M; Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium., Dogné JM; Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium., Douxfils J; Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium.; Qualiblood s.a., Research and Development Department, Namur, Belgium.; Department of Biological Hematology, Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France.
Jazyk:	angličtina
Zdroj:	Heliyon [Heliyon] 2024 Aug 10; Vol. 10 (16), pp. e36116. Date of Electronic Publication: 2024 Aug 10 (Print Publication: 2024).
DOI:	10.1016/j.heliyon.2024.e36116
Abstrakt:	Introduction: Some studies suggest that the monovalent mRNA-1273 vaccine is more effective than BNT162b2 in producing higher levels of antibodies. However, limited data are available, and the methods used are not directly comparable. Material and Methods: Blood samples were obtained before the booster (third dose) and after 14, 90, and 180 days in two similar cohorts who received the original BNT162b2 or mRNA-1273 vaccine designed to target wild type SARS-CoV-2. The aim of our study is to compare their effectiveness by assessing the levels of binding and neutralizing antibodies specifically against each of the BA.1 variant, BA.5 variant, and the XBB.1.5 subvariant. Results: Once the peak was reached after two weeks, a drastic decline in binding and neutralizing antibodies was observed up to 6 months after the homologous booster administration. The humoral response was however more sustained with the mRNA-1273 booster, with half-lives of 167, 55, and 48 days for binding, BA.1, and BA.5 neutralizing antibodies compared to 144, 30, and 29 days for the BNT162b2 booster, respectively. Compared to the BA.1 variant, the neutralizing capacity was significantly decreased at 6 months with the BA.5 variant (fold-decrease: 1.67 to 3.20) and the XBB.1.5. subvariant (fold-decrease: 2.86 to 5.48). Conclusion: Although the decrease in the humoral response was observed with both mRNA vaccines over time, a more sustained response was observed with the mRNA-1273 vaccine. Moreover, the emergence of Omicron-based variants causes a reduced neutralizing capacity, notably with the XBB.1.5. subvariant. The administration of subsequent boosters would therefore be needed to restore a sufficiently high neutralizing response. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu